Volixibat
Cholestatic Liver Diseases (e.g., Primary Sclerosing Cholangitis)
Phase 2b/3SELECT Study (Known from external sources)
Key Facts
Indication
Cholestatic Liver Diseases (e.g., Primary Sclerosing Cholangitis)
Phase
Phase 2b/3
Status
SELECT Study (Known from external sources)
Company
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is dedicated to addressing severe unmet needs in rare liver diseases through its expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully commercialized LIVMARLI® and is advancing a robust clinical pipeline, including brelovitug for chronic hepatitis delta virus. With a patient-centric approach and a seasoned leadership team, Mirum aims to deliver life-changing medicines to underserved patient communities globally.
View full company profile